In recent years, neurotrophic factors have emerged as promising therapeutic tools for neurodegenerative diseases, owing to their effects on the promotion of survival, differentiation and phenotype of neurons. Among these agents, the dopaminotrophic glial cell linederived neurotrophic factor (GDNF) 1 has received special attention because of its possible usefulness in the treatment of Parkinson's disease 2 . In rodent and primate models, GDNF has been shown to protect dopaminergic nigrostriatal neurons from neurotoxins and to induce fiber outgrowth when administered directly into the brain [3] [4] [5] [6] [7] [8] . GDNF also protects other neurons from neurotoxic damage, particularly noradrenergic cells in the locus coeruleus, which are affected in early stages of Parkinson's disease as well as in Alzheimer's disease and other brain disorders 9 . Two open-label clinical trials have evaluated the therapeutic effects of intrastriatal GDNF infusion in patients with Parkinson's disease with encouraging clinical and neurochemical results 10, 11 . However, a randomized, placebo-controlled trial performed in patients with Parkinson's disease was halted because of safety concerns 12 . GDNF-based therapies are still considered to be promising for Parkinson's disease and other neurodegenerative diseases 13 , although improvement in their effectiveness requires an understanding of the actual physiologic role of GDNF in the maintenance of catecholaminergic neurons in adult life, thus far essentially unknown.
Gdnf mRNA is found in several regions of the adult rodent brain 9, 14 , and, within the peripheral nervous system, GDNF is highly concentrated in the adult carotid body 15, 16 , a dopaminergic organ used in autotransplantation studies on Parkinson's disease [17] [18] [19] . Research on genetically modified animal models in which the GDNF signaling pathway is disrupted has thus far failed to provide definitive information on the physiological neuroprotective action of GDNF in adult life. Homozygous Gdnf knockout mice die during the early postnatal period owing to agenesis of the kidneys and myenteric plexus. At birth, Gdnf -/-mice show normal numbers of catecholaminergic neurons in the substantia nigra and locus coeruleus, thus suggesting that compensatory neuroprotective mechanisms may be activated during development [20] [21] [22] . Heterozygous (Gdnf +/-) mice are fertile and develop normally, although they manifest an accelerated decline in spontaneous motor activity and coordination with age 23 . Nevertheless, this embryonic GDNF deficit seems to have little impact in the adult, as, at 20 months of age, the mice show only a 15% decrease of tyrosine hydroxylase (TH)-positive substantia nigra neurons and no differences in striatal TH + fiber density with respect to controls 23 . Gdnf +/-mice, however, seemed to show a higher susceptibility to neurotoxin-induced long-term degeneration of monoaminergic neurons than wild-type littermates 24 . Region-specific genetic deletion (driven by the promoter from the dopamine transporter gene) of Ret, a component of the GDNF receptor complex, in dopaminergic neurons has provided conflicting results regarding the role of this pathway in maintenance of adult neurons. A comparative morphometric and biochemical analysis of dopaminergic nigrostriatal neurons in adults of these Ret-null mice versus controls showed no differences 25 . Another group has reported that embryonic deletion of Ret in catecholaminergic neurons results in a significant decrease of TH + substantia nigra neurons and striatal nerve terminals at 2 years of age, although, unexpectedly, neurons in the ventral tegmental area (VTA) and locus coeruleus remained unaffected 26 .
Here, we report the generation of a conditional GDNF-null mouse in which GDNF expression was markedly reduced in adulthood, hence avoiding the establishment of developmental compensatory modifications masking the true physiologic action of GDNF in the adult nervous system. These mice show selective and extensive catecholaminergic neuronal death, most notably in the locus coeruleus, substantia nigra and VTA. GABAergic and cholinergic pathways appear to be unaffected. The neurochemical and histological alterations in GDNFdeprived mice induce the progressive appearance of behavioral motor disturbances. These data unequivocally indicate that endogenous GDNF is absolutely required for trophic maintenance of catecholaminergic neurons in normal adult rodents.
RESULTS

Neurochemical alterations in conditional GDNF knockout mice
To generate a 'floxed' Gdnf allele (Gdnf F ), we designed a targeting construct containing the mouse Gdnf exon 3 flanked by loxP sites and neomycin resistance (neo) markers (Fig. 1a) . Embryonic stem (ES) cells were electroporated with this construct and homologous recombination with the wild-type locus resulted in the targeted (floxed) allele Gdnf F . Positive clones of ES cells were selected by neomycin resistance and analyzed by Southern blotting for proper integration of the floxed allele (Fig. 1a,b) . Routine genotyping of mice carrying the wild-type and floxed alleles was done by PCR (Fig. 1a,c) . Gdnf F/+ mice were interbred with Gdnf +/-mice carrying the Esr1-cre transgene 27 . In the resulting Gdnf F/-;Esr1-cre (cGdnf ) offspring, we administered tamoxifen (TMX) at 2 months of age to activate the ubiquitously expressed Cre recombinase, thus switching off GDNF expression. We experimentally verified the appearance of the GDNF-null allele in the germ line of TMX-treated mice (see Methods). Mice were killed at 1, 3 or 7 months after TMX treatment for GDNF protein measurements, DNA and RNA analyses, and histological studies (Fig. 1d) . Confirmation for the excision of the floxed allele in adulthood was done by PCR of striatal DNA using specific probes (Fig. 1a,e) . The proportion of wild-type Gdnf alleles that remained in striatal neurons after TMX treatment was estimated by quantitative PCR (Q-PCR) to be 18% of that in control mice (relative values, 0.18 ± 0.06, n ¼ 5 TMX-treated mice versus 1.00 ± 0.22, n ¼ 3 untreated mice; P o 0.05).
We evaluated Gdnf mRNA expression in the various mouse strains by quantitative RT-PCR (QRT-PCR) on whole brain extracts (Fig. 1f) . Embryonic Gdnf heterozygosity resulted in a mild, nonsignificant decrease of total brain Gdnf mRNA that was similar in Gdnf +/-and Gdnf F/-strains, thus indicating that the floxed and wild-type Gdnf alleles were transcribed with similar efficiency. In these two embryonic heterozygous mouse strains, however, Gdnf mRNA was 75% the amount seen in the wild-type mice, thus indicating compensatory activation by the remaining normal allele. Administration of TMX had no effect on wild-type mice, but in cGdnf mice, it induced a marked (B60% with respect to wild-type mice; P o 0.01) reduction of Gdnf mRNA (Fig. 1f) . Besides these mRNA measurements, we also estimated the concentration of GDNF protein in homogenates of striatum, a region of the adult rodent brain with high GDNF expression 9, 16 , using a highly sensitive ELISA. In fair agreement with the mRNA data, TMX induced an B60% decrease of striatal GDNF content with respect to controls (Fig. 1g) . These results suggest that although TMX treatment of cGdnf mice left only B18% of alleles unaffected, the mice were able to produce up to B40% of the normal amount of GDNF mRNA and protein. As explained above, this probably reflects compensatory transcriptional upregulation of the functional Gdnf allele in the embryonic Gdnf F/-mice. GDNF depletion produced a selective decrease of brain Th mRNA content, leaving choline acetyltransferase (Chat) and glutamic acid decarboxylase (Gad1) mRNA levels unaltered (Fig. 1h) . The data demonstrated a substantial decrease of brain GDNF in the conditional Gdnf knockout mouse and suggested the existence in these mice of catecholaminergic cell damage without an affect on cholinergic or GABAergic neurons.
Selective neuronal death in GDNF-depleted adult brain To evaluate the impact of TMX treatment and subsequent GDNF depletion on neuronal viability, we performed stereological cell counts in brain regions, such as the substantia nigra, VTA and locus coeruleus, containing catecholaminergic neurons whose vulnerability to neurotoxins is prevented by GDNF 3, 8, 9, 24 (Figs. 2 and 3 and Table 1 ). Embryonic Gdnf heterozygous mice (Gdnf F/-strain) showed no effect on the number of TH + neurons in the substantia nigra, VTA and locus Figure 1 Molecular characterization of the conditional Gdnf knockout mice. coeruleus compared with controls (Gdnf F/+ strain, Table 1 ). Deletion of the floxed Gdnf allele with TMX gave rise, however, to a progressive reduction in the number of TH + cells in substantia nigra and VTA. On average, the decrease in TH + neurons was small and statistically nonsignificant at 1 month after TH treatment but was very pronounced (B60-70% TH + cell reduction) at 7 months after Gdnf gene deletion ( Fig. 2a-d and Table 1 ). In parallel with the reduction in TH + cell number, we observed a clear and significant decrease in the total number of neurons both in the substantia nigra and VTA (Fig. 2e-h and Table 1 ). These observations indicate that the decrease of TH + cells in Gdnf knockout mice did not simply reflect downregulation of Th gene expression. The disappearance of mesencephalic TH + neurons was accompanied by diminishment of TH + striatal nerve terminal density, particularly in the ventral region ( Table 1) . Progressive neuronal death in GDNF-deprived mice was particularly pronounced in the locus coeruleus: evidence of TH + neurons in this nucleus almost disappeared in cGdnf at 7 months after TMX treatment, and the total number of Nissl + neurons in the nucleus decreased markedly (Fig. 3a-f and Table 1 ). numbers in structures of the peripheral nervous system such as the carotid body (Fig. 4a,b and Table 1 ) and the superior cervical ganglion (SCG; Table 1 ).
Neuronal loss observed in cGdnf mice was not general but restricted to the aforementioned brain areas. For example, the number of TH + cells in the arcuate nucleus, a component of the hypothalamic dopaminergic system, was unchanged (Fig. 4c-e and Table 1) , and no gross histological alterations were observed in the hippocampus or in neocortical regions ( Supplementary Fig. 1 online) . TMX treatment did not elicit macroscopic anatomical modifications in gut or kidney in mice studied up to 8 months after TMX treatment. Similarly, we did not observe changes in weight of TMX-treated cGdnf mice; weight was maintained unaltered during the first 3-4 months despite the ongoing neurodegenerative process (respectively, 22.3 ± 1 g, n ¼ 3, versus 22.6 ± 0.4, n ¼ 4, wild-type and GDNF-depleted mice studied 134 d after TMX treatment).
Although not yet studied in detail, body weight did, however, seem to decrease in older (4200 d after TMX treatment) Gdnf knockout mice.
Given the clear dependence on GDNF of mesencephalic dopaminergic and noradrenergic neuronal survival, we searched for the location of putative targets constitutively expressing high levels of GDNF and therefore critical for the trophic maintenance of the cells. To this end, we used the heterozygous Gdnf lacZ mouse, a tool that allowed us to identify cells with high levels of GDNF expression by the characteristic blue X-gal staining 16, 22 . After systematic analysis of the brain, we consistently found X-gal deposits in cells distributed throughout the striatum, in the anteroventral (particularly the ventrolateral region) and anteromedial nuclei of the thalamus, as well as in the septum (mainly in the mediolateral region) ( Supplementary  Fig. 2a-e online) . These structures are innervated by projections from catecholaminergic neurons of the substantia nigra, VTA and locus coeruleus 28, 29 . Unexpectedly, high GDNF expression was also observed in the subcommissural organ (SCO; Supplementary Fig. 2f,g ), an ependymal secretory gland located in the roof of the third ventricle that participates in cerebrospinal fluid homeostasis 30 .
Behavioral motor abnormalities in GDNFdepleted mice To assess the motor performance of the conditional Gdnf knockout mice, we used open field tests [31] [32] [33] [34] . We analyzed horizontal and vertical locomotor activity, with estimation of the distance traveled and time spent walking, as well as the number and duration of rearings. These are well-established behavioral tests used to characterize animals with deficits in the dopaminergic nigrostriatal pathway [31] [32] [33] [34] .
GDNF-depleted mice showed a clear hypokinetic syndrome, progressively aggravated with time after TMX treatment. In fair agreement with the histological data (see Figs. 2-4 and Table 1 ), open field impairments were mild during the first weeks after TMX treatment but became quite obvious after three to four months of GDNF deprivation (Fig. 5) . Although the number of cases studied so far is still small, the data available strongly suggested that the motor deficits continued to progress as TMX treated cGdnf mice got older.
DISCUSSION
The results demonstrate that endogenous GDNF exerts an indispensable neurotrophic effect on catecholaminergic neurons of the adult mouse nervous system, particularly with respect to the ventral mesencephalic dopaminergic neurons in the substantia nigra and VTA as well as the noradrenergic cells in the locus coeruleus. The dependence of neuronal survival on GDNF is observed despite the trophic factor being downregulated, on average, to only 40% of its content in normal adult brain. It has previously been shown that intracerebral administration of exogenous GDNF can protect catecholaminergic neurons from toxic damage and that striatal overexpression of GDNF induces sprouting of dopaminergic fibers 3,4,6-9 . It had also been reported that postnatal survival and phenotypic expression of ventral mesencephalic dopaminergic neurons in tissue explants is favored by GDNF 35 . However, the actual physiologic role of GDNF in preserving adult brain catecholaminergic cells in vivo has, until now, been unknown. Our results contrast with the virtual absence of neuronal damage in GDNF heterozygotes or in mice without canonical GDNF (Ret) receptors 20, 23, 25, 26 . Hence, it seems highly likely that embryonic gene disruption of the GDNF signaling pathway induces developmental compensatory mechanisms involving other neurotrophic factors and/ or GDNF receptors. The existence of Ret-independent GDNF receptors in adult mammalian brain is well documented 14, 36 , and it has also been shown that both in vitro and in vivo effects of GDNF on midbrain dopaminergic neurons can be antagonized with function-blocking antibodies to NCAM 37 . Thus, our findings support the idea that GDNF receptors other than Ret could play a significant physiologic role in adult brain.
The strict dependence of adult catecholaminergic neuronal survival on endogenous GDNF prompted us to search for brain areas with high GDNF expression. Using a genetic marker 16, 22 , we have demonstrated that, besides the striatum, GDNF is highly expressed in the septum as well as in the anteroventral and anteromedial thalamus, preferential targets of projections from catecholaminergic neurons of the substantia nigra, VTA and locus coeruleus 28, 29 . These same brain areas have already been shown to express high Gdnf mRNA levels using northern analysis and in situ hybridization techniques 9, 14 . Notably, we have also seen a previously unnoticed robust GDNF expression in the SCO, an enigmatic glially derived secretory gland in the third ventricle that participates in cerebrospinal fluid homeostasis 30, 38 . The actual physiologic role of GDNF in SCO cells is an open question that must be addressed in future experimental work.
The clear reliance of adult mammalian mesencephalic catecholaminergic neurons on the continuous supply of GDNF further supports its potential use as a therapeutic agent in Parkinson's disease and possibly in other neuronal disorders 2 . In this regard, delivering GDNF to several targets (striatum, thalamus and septum), mimicking the physiologic trophic activation of catecholaminergic cells, rather than delivering it solely to the striatum, may improve the efficacy of current clinical protocols. In addition, the pattern of cell death induced by GDNF downregulation in adult brain recapitulates many of the neuropathological hallmarks of Parkinson's disease. Besides progressive dopaminergic cell death in substantia nigra and VTA, this phenotype is particularly evident in the locus coeruleus, a region known to contribute to the pathophysiology of Parkinson's disease that degenerates early in the progression of the disease 9, 39 . Notably, dopaminergic neurons in the hypothalamic arcuate nucleus, unaffected in Parkinson's disease 40 , were also preserved in GDNF-null adult mice. In parallel with the histological modifications, GDNF-depleted mice progressively develop a hypokinetic phenotype, similar to that reported in mice with toxic damage of the nigrostriatal pathway and locus coeruleus [31] [32] [33] 41 , which is fully compatible with the behavioral changes seen in Parkinson's disease. Hence, the conditional Gdnf knockout mouse model should facilitate the understanding of neuroprotective pathways induced by GDNF and the study of Parkinson's disease pathogenesis, as well as the development of new types of therapeutic tools to fight neurodegeneration.
METHODS
Generation of mouse models. Mice were housed under temperaturecontrolled conditions (22 1C) in a 12 h light/dark cycle. All experiments were performed in accordance with institutional guidelines approved by the ethics committee of the Hospital Universitario Virgen del Rocio. To generate the conditional Gdnf mice, we engineered a targeting construct that could be homologously recombined into the third coding exon of the Gdnf locus. The targeting construct contained Gdnf exon3 flanked by loxP sites (Gdnf F ) and the neo resistance marker. For homologous recombination, we used 129Sv-derived R1 ES cells. Southern blotting using a DNA 3¢ probe was used to identify the recombined allele. Gdnf F mice were further propagated and used for experiments on a mixed genetic background (129/SvJ:C57BL/6). Routine genotyping to detect the wild-type or floxed allele was performed using PCR. Floxed PCR was performed with the primers loxP15 (5¢-TCACGTGTCTATGTGCTAAA-3¢) and loxP13 (5¢-AATGATCATTTCGGGCAGTC-3¢). To obtain the experimental model used in this study, Gdnf lacZ mice (Gdnf +/-) 22 were mated with mice carrying one copy of the Esr1-cre gene (ref. 27 ) to obtain Gdnf +/-;Esr1-cre F 1 progeny. F 1 mice were mated with Gdnf F/+ mice to generate control (Gdnf F/+ ) and experimental (Gdnf F/-;Esr1-cre, or cGdnf) littermates. Two-month-old mice were intraperitoneally injected with TMX (Sigma; 0.2 mg per d and per g body weight) for four consecutive days. TMX was prepared and used as previously described 42 . cGdnf mice without TMX treatment were used as controls when indicated. To test for the successful conditional deletion of Gdnf in vivo, we used excised PCR with the primers loxP15 and loxP23 (5¢-GAACTCCAGGTAAATAATCC-3¢). To verify the effect of TMX and the proper excision at the Gdnf F locus, we mated Gdnf F/+ ;Esr1-cre mice treated with TMX with wild-type mice. Heterozygous Gdnf +/-mice in the progeny were crossed and, as expected, the resulting offspring carrying the two excised alleles died during the first postnatal day due to renal agenesis. DNA extraction from brain paraffin slices. We deparaffined 20-mm-thick paraffin-embedded striatal slices twice with xylene and hydrated by washing with solutions containing decreasing concentrations of ethanol. Four slices were digested for 2 h at 55 1C in 200 ml of directPCR reagent (Viagen) containing proteinase K (15 mg/ml). Proteinase K was inactivated by heating samples at 85 1C for 2 h. We used 1 ml from the resulting DNA solution for PCR analysis.
Quantitative RT-PCR. To determine Gdnf, Th, Chat and Gad1 mRNA levels, brain RNA was extracted using TRIzol reagent (Invitrogen) in a homogenizer (Omni 2000). RNA samples (5 mg) were treated with RNase-free DNase (GE Healthcare) and copied to cDNA using SuperScriptII reverse transcriptase (Invitrogen) in a final volume of 20 ml. Real time PCR was performed in an ABI Prism 7500 Sequence Detection System (Applied-Biosystems) using SYBR Green PCR Master mix (Applied-Biosystems) and the thermocycler conditions recommended by the manufacturer. PCR reactions were performed in duplicates in a total volume of 25 ml containing 1 ml of the reverse transcription reaction. In each sample, Actb and Ppia RNA levels were estimated to normalize for RNA input amounts. Relative quantifications using both housekeeping genes produced similar results. To normalize mRNA levels in knockout mice to those in control samples, we calculated an average cycle threshold of the control samples and processed all the samples in the experiment relative to this average cycle threshold. To estimate DNA recombination at the Gdnf locus, we performed Q-PCR on DNA samples extracted from striatal paraffin-embedded slices. The excision of the floxed allele was calculated estimating neo gene dosage after TMX treatment. DNA amounts were normalized to b-glucuronidase (Gusb) levels. Primers used for Q-PCR appear in Supplementary  Table 1 online.
GDNF ELISA. Striatal GDNF protein content was estimated using a commercial ELISA kit (GDNF Emax Immunoassay System; Promega). Brain was removed and immediately frozen in liquid nitrogen. Left and right striata were dissected out, placed in 200 ml of 20 mM Tris HCl, pH 7.6, 150 mM NaCl, 0.05% (vol/vol) NP-40 and proteinase inhibitor cocktail (SIGMA), and sonicated with a Branson-150 Sonifier for 10 s (output 2-3). Samples were centrifuged at 4 1C for 10 min at maximal speed in a microcentrifuge and supernatant were removed and frozen. Protein concentration was performed with Bio-Rad protein quantification kit and 100 mg of protein were used in the assay. ELISA was performed following the manufacturer's protocol. Neonatal (P1) protein extracts of forebrains from wild-type and Gdnf -/-mice were used as positive and negative controls. Absorbance from Gdnf -/-extracts was subtracted to each individual measurement. GDNF content was estimated in left and right striata and an average per mouse was used to perform comparative analysis.
Tissue preparation and histochemistry. Mice were anesthetized and killed by perfusion with 4% paraformaldehyde. The brain and the carotid bifurcation were extracted and paraffin-embedded. Coronal mouse brain sections (thickness: 20 mm) were used for TH or NeuN-TH immunohistochemistry or for Nissl staining (0.1% cresyl violet) in quantitative and morphometric studies. The Envision + kit (DAKO) was used for immunohistochemistry according to the recommended manufacturer's protocol. Antibodies and the dilution factors used were as follows: polyclonal antibody to TH (Pel-Freez), 1:1,000 and monoclonal antibody to NeuN (Chemicon), 1:200. For double labeling with anti-TH and anti-NeuN, we incubated the slices with antibodies to mouse antibodies and the signal was developed with 3,3-diaminobenzidine (DAKO).
To increase contrast, a diaminobenzidine enhancer (DAKO) was used. Antibodies to rabbit antibodies were added in a second step and the reaction developed with b-amino-9-ethyl-carbazole substrate (DAKO). b-galactosidase staining of 50-mm-thick brain slices was performed as described previously 16, 22 .
Stereological cell counts. We counted TH-immunoreactive, NeuN-immunoreactive and Nissl-positive neurons in 20-mm-thick coronal microtome sections spaced 40 mm apart throughout the extent of the arcuate nucleus, substantia nigra, VTA and locus coeruleus, following procedures similar to those previously used in our laboratory 43 . Striatal TH + fiber density was quantified in a 20 mm-thick slice at 0.86 mm anterior to bregma 44 . The striatum was divided into dorsal and ventral areas and 10-20 random 3,565 mm 2 dissectors per hemisphere were counted using the C.A.S.T. Grid System. Carotid body TH + cell counting was performed across the entire carotid body parenchyma. SCG TH + neurons were counted on 30-mm-thick coronal sections spaced 90 mm apart throughout the extent of the structure. Random dissectors of 5,348 mm 2 were used.
Open field. For behavioral assessment for motor dysfunction, we used N7 C57BL/6 mice for open-field analysis in a box with a 22.5 cm Â 22.5 cm floor and 42-cm-high walls. Four boxes were monitored at the same time using an automatic tracking system (SMART, Panlab). Mice were recorded for 60 min and several horizontal motor parameters were calculated using the SMART software (version 2.5.14). Vertical movements were estimated by visual inspection of the recorded videos using the specific tool provided by the software (SMART).
Statistical analysis. Data are presented as mean ± s.e.m. and were analyzed with either Student's t-test or one-way analysis of variance followed by Tukey's test. P o 0.05 was considered statistically significant.
